Antibiotic Resistance Market By Resistant Bacteria Type (Pseudomonas Aeruginosa, Clostridioides difficile (C. difficile), Carbapenem-resistant Enterobacteriaceae (CRE), Streptococcus pneumoniae (S. pneumoniae), Acinetobacter, Vancomycin-resistant Enterococci (VRE), Mycobacterium Tuberculosis (TB), Neisseria gonorrhoeae (N. gonorrhoeae), and Others); By Disease Indication (Complicated Urinary Tract Infections (cUTI), Complicated Intra-Abdominal Infections (cIAI), Community-Acquired Bacterial Pneumonia (CABP), Acute Skin and Skin Structure Infections (ABSSSI), Multidrug-Resistant (MDR) & Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB & XDR-TB), Sepsis, Clostridium Difficile (C. difficile) Infections, and Others); By Drug Class (Antimycobacterials, Fluoroquinolones, Oxazolidinones, Tetracyclines, Penicillins, Antifolates, Combination Treatment, and Others); By Route of Administration (Oral, Topical, Intramuscular, and Intravenous (IV)); By End Use (Home Care, Healthcare Facilities, and Others); By Region (By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
A subset of antimicrobial resistance (AMR), the term antibiotic resistance applies to bacteria that become resistant to antibiotics. As resistant microbes are more difficult to treat, they require higher doses, or alternative medications which can either be toxic or might come with side-effects that may not have been anticipated by doctors. Such treatments can also be more expensive. Microbes that are resistant to multiple antimicrobials are called multidrug resistant (MDR). The research to explore new treatments for bacteria with antibiotic resistance is expected to rise and attract investment, which showcases significant growth potential for global antibiotic resistance market over the forecast period. The major factor that is restraining the growth of global antibiotic resistance market is the stringent regulatory procedure, along with cost concerns. With the regulatory process for new drugs to navigate being long and difficult, antibiotics are considered as short term treatments.
The COVID-19 pandemic has led to a tremendous rise in concern because there are many factors that are leading to increase in the number of patients, including coronavirus patients. According to a study, about 70% of hospitalized COVID-19 patients are receiving antibiotics. Empiric broad-spectrum antibiotic therapy is often offered to them. Many times, hospitalized COVID-19 patients develop a secondary bacterial infection for which, antibiotic therapy becomes necessary. This leads to increased use of antibiotics such as azithromycin and teicoplanin because currently, clear guidelines for the treatment of COVID-19 patients are absent in most countries. The possibility of complications that coronavirus might cause in the health of a patient makes it difficult for experts to decide that antimicrobial agents could be prescribed for a patient. As the use of antibiotics has increased in nursing homes and other long-term care facilities, doctors are trying to see which symptoms of coronavirus can be cured from these antibiotics.
The rising antibiotic drug resistance infections, increase in clinical developments of antibiotic resistance, along with increase in global initiatives to control drug-resistance is driving the growth of global antibiotic resistance market. The policies for the development of new therapies for growing burden and severity of antibiotic-resistant infections showcase potential opportunities for the global antibiotic resistance market growth over the future years.
In terms of revenue, antibiotic resistance market was valued at US$ 8417.36 Mn in 2020 growing at a CAGR of 4% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Antibiotic Resistance Market Revenue & Forecast, (US $ Million), 2021 – 2029
Resistant Bacteria Type Outlook:
By resistant bacteria type, this research report from Absolute Markets Insights about global antibiotic resistance market covers pseudomonas aeruginosa, clostridioides difficile (C. difficile), carbapenem-resistant enterobacteriaceae (CRE), streptococcus pneumoniae (S. pneumoniae), acinetobacter, vancomycin-resistant enterococci (VRE), mycobacterium tuberculosis (TB), neisseria gonorrhoeae (N. gonorrhoeae), and others. In 2020, the carbapenem-resistant enterobacteriaceae (CRE) held the larger market share.
During the forecast period, clostridioides difficile (C. difficile) category is estimated to witness highest growth rate in the market. The treatment of Clostridium difficile infection is a big concern. C. difficile infection leads to approximately 453,000 cases and 29,000 deaths every year in the USA. In 2017, approximately 223,900 cases of C. difficile occurred in USA. At least 12,800 people died in 2017 due to this. Although C. difficile is an important pathogen associated with diarrhoea, however, in past few years, an increase in the occurrence of C. difficile infection (CDI) outside hospital settings have also been reported.
Disease Indication Outlook:
The disease indication segment in the global antibiotic resistance market has been broadly segmented into complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), community-acquired bacterial pneumonia (CABP), acute skin and skin structure infections (ABSSSI), multidrug-resistant (MDR) and pulmonary extensively drug resistant (XDR) tuberculosis (TB) (MDR-TB and XDR-TB), sepsis, clostridium difficile (C. difficile) infections, and others. In 2020, complicated urinary tract infections (cUTI) category held the largest market share. During the forecast period, community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI) are anticipated to wtiness substantial growth rate. There is an increase in hospitalization due to ABSSSI which has been caused by resistant pathogens. To cure them, there is a need for new treatment options. Approved by the U.S. Food and Drug Administration (FDA) in 2016, dalbavancin, oritavancin, and tedizolid phosphate are being used for the treatment of ABSSSI. ABSSSI treatment includes an antibiotic therapy, antimicrobial therapy, and surgical drainage. Some therapeutic approaches are being favoured in treating skin infections including adjunctive therapies, early & appropriate empiric antibiotic therapy, surgical drainage & debridement, and wound culture with susceptibility testing. In several countries including USA, many deaths and hospitalizations have occurred due to CABP. It spreads rapidly in the areas having dense and aging population, and heavily affects people with low immunity. In the era of China-originated coronavirus pandemic, when lower immunity is causing big time trouble, people are cautious about diseases that can affect someone only because of lower immunity.
Drug Class Outlook:
This market report segments the drug class segment of global antibiotic resistance market into antimycobacterials, fluoroquinolones, oxazolidinones, tetracyclines, penicillins, antifolates, combination treatment, and others. In 2020, the antifolates category held the larger market share. During the forecast period, combination treatment category can make progress as the fastest growing market category due to the increased use of these therapies for the treatment of gram-negative infections as these infections have limited treatment options. Combination treatment includes fixed-dose combinations of beta-lactams and beta-lactamase inhibitors. Demand for customized treatment is increasing as monotonous treatment and traditional treatment is not effective against bacteria and viruses, who have developed resistance against familiar treatments. Hence, the combination of two or three different treatment is effective many times.
Route of Administration Outlook:
Based on route of administration, the global antibiotic resistance market is classified into oral administration, topical administration, intramuscular administration, and intravenous (IV) administration. In 2020, the oral administration segment occupied larger market share. During the forecast period, the intravenous (IV) administration is anticipated to witness highest growth rate. Several medications, especially antibiotic medicines, are more effective only when they directly react with blood so that they can counter the infection more effectively.
End Use Outlook:
On the basis of end use, the global antibiotic resistance market is segmented into home care, healthcare facilities, and others. In 2020, the healthcare facilities category held the larger market share and is anticipated to retain the growth rate over the period of next eight years. However, oral medications for home care are also being considered to prescribed to patients suffering from chronic conditions.
Region Outlook:
In 2020, North America accounted for the largest share in the global antibiotic resistance market. During the forecast period, Asia Pacific region is estimated to register highest growth rate due to rising number of antibiotic-resistant infections and hospital-acquired infections in many Asian countries. Lack of sanitation in many countries in this region has contributed to environment suitable for various viruses and pathogens to flourish and cause many diseases. A 2017 survey found that in the Asia Pacific region, one strain of bacteria had developed resistance to levofloxacin which is an antibiotic used to treat a wide variety of infections. The resistance grew from roughly 2% before 2000 to 27% between 2011 and 2015. Other factors that are leading to market growth in the Asia Pacific region include increased antibiotics consumption, easy availability of antibiotics, and rise in sale of over-the-counter drugs.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of global antibiotic resistance market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some key players in the global antibiotic resistance market are Allergan Pharma Co., GlaxoSmithKline PLC., Johnson & Johnson Services Inc., MELINTA THERAPEUTICS - THE ANTIBIOTICS COMPANY, Merck & Co. Inc., Mylan N.V., Nabriva Therapeutics PLC, Otsuka Novel Products GmbH, Pfizer Inc., and Sandoz AG amongst others.
Global Antibiotic Resistance Market:
By Resistant Bacteria Type
- Pseudomonas Aeruginosa
- Clostridioides difficile (C. difficile)
- Carbapenem-resistant Enterobacteriaceae (CRE)
- Streptococcus pneumoniae (S. pneumoniae)
- Acinetobacter
- Vancomycin-resistant Enterococci (VRE)
- Mycobacterium Tuberculosis (TB)
- Neisseria gonorrhoeae (N. gonorrhoeae)
- Others
By Disease Indication
- Complicated Urinary Tract Infections (cUTI)
- Complicated Intra-Abdominal Infections (cIAI)
- Community-Acquired Bacterial Pneumonia (CABP)
- Acute Skin and Skin Structure Infections (ABSSSI)
- Multidrug-Resistant (MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB and XDR-TB)
- Sepsis
- Clostridium Difficile (C. difficile) Infections
- Others
By Drug Class
- Antimycobacterials
- Fluoroquinolones
- Oxazolidinones
- Tetracyclines
- Penicillins
- Antifolates
- Combination Treatment
- Others
By Route of Administration
- Oral
- Topical
- Intramuscular
- Intravenous (IV)
By End Use
- Home Care
- Healthcare Facilities
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target
Audiences
3. Research
Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations
and Insights from AMI’s Perspective**
5. Holistic
Overview of Antibiotic Resistance Market
6. Market
Synopsis: Antibiotic Resistance Market
7. Antibiotic
Resistance Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Antibiotic Resistance Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Antibiotic Resistance Market
7.6. Porter’s Five Force Analysis
7.7. Impact of
Covid-19 on Antibiotic Resistance Market
8. Global
Antibiotic Resistance Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global
Antibiotic Resistance Market Revenue (US$ Mn)
8.2. Global
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
8.2.1. Pseudomonas
Aeruginosa
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2020
8.2.1.3. Market
Forecast, 2021 – 2029
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2020
8.2.1.5.1.2. Market
Forecast, 2021 – 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2020
8.2.1.5.2.2. Market
Forecast, 2021 – 2029
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2020
8.2.1.5.3.2. Market
Forecast, 2021 – 2029
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2020
8.2.1.5.4.2. Market
Forecast, 2021 – 2029
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2020
8.2.1.5.5.2. Market
Forecast, 2021 – 2029
8.2.2. Clostridioides
difficile (C. difficile)
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2020
8.2.2.3. Market
Forecast, 2021 – 2029
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2020
8.2.2.5.1.2. Market
Forecast, 2021 – 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2020
8.2.2.5.2.2. Market
Forecast, 2021 – 2029
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2020
8.2.2.5.3.2. Market
Forecast, 2021 – 2029
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2020
8.2.2.5.4.2. Market
Forecast, 2021 – 2029
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2020
8.2.2.5.5.2. Market
Forecast, 2021 – 2029
8.2.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 – 2020
8.2.3.3. Market
Forecast, 2021 – 2029
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 – 2020
8.2.3.5.1.2. Market
Forecast, 2021 – 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2020
8.2.3.5.2.2. Market
Forecast, 2021 – 2029
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2020
8.2.3.5.3.2. Market
Forecast, 2021 – 2029
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2020
8.2.3.5.4.2. Market
Forecast, 2021 – 2029
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 – 2020
8.2.3.5.5.2. Market
Forecast, 2021 – 2029
8.2.4. Streptococcus
pneumoniae (S. pneumoniae)
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2015 – 2020
8.2.4.3. Market
Forecast, 2021 – 2029
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2015 – 2020
8.2.4.5.1.2. Market
Forecast, 2021 – 2029
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 – 2020
8.2.4.5.2.2. Market
Forecast, 2021 – 2029
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2015 – 2020
8.2.4.5.3.2. Market
Forecast, 2021 – 2029
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 – 2020
8.2.4.5.4.2. Market
Forecast, 2021 – 2029
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2015 – 2020
8.2.4.5.5.2. Market
Forecast, 2021 – 2029
8.2.5. Acinetobacter
8.2.5.1. Definition
8.2.5.2. Market
Estimation and Penetration, 2015 – 2020
8.2.5.3. Market
Forecast, 2021 – 2029
8.2.5.4. Compound
Annual Growth Rate (CAGR)
8.2.5.5. Regional
Bifurcation
8.2.5.5.1. North
America
8.2.5.5.1.1. Market
Estimation, 2015 – 2020
8.2.5.5.1.2. Market
Forecast, 2021 – 2029
8.2.5.5.2. Europe
8.2.5.5.2.1. Market
Estimation, 2015 – 2020
8.2.5.5.2.2. Market
Forecast, 2021 – 2029
8.2.5.5.3. Asia
Pacific
8.2.5.5.3.1. Market
Estimation, 2015 – 2020
8.2.5.5.3.2. Market
Forecast, 2021 – 2029
8.2.5.5.4. Middle
East and Africa
8.2.5.5.4.1. Market
Estimation, 2015 – 2020
8.2.5.5.4.2. Market
Forecast, 2021 – 2029
8.2.5.5.5. Latin
America
8.2.5.5.5.1. Market
Estimation, 2015 – 2020
8.2.5.5.5.2. Market
Forecast, 2021 – 2029
8.2.6. Vancomycin-resistant
Enterococci (VRE)
8.2.6.1. Definition
8.2.6.2. Market
Estimation and Penetration, 2015 – 2020
8.2.6.3. Market
Forecast, 2021 – 2029
8.2.6.4. Compound
Annual Growth Rate (CAGR)
8.2.6.5. Regional
Bifurcation
8.2.6.5.1. North
America
8.2.6.5.1.1. Market
Estimation, 2015 – 2020
8.2.6.5.1.2. Market
Forecast, 2021 – 2029
8.2.6.5.2. Europe
8.2.6.5.2.1. Market
Estimation, 2015 – 2020
8.2.6.5.2.2. Market
Forecast, 2021 – 2029
8.2.6.5.3. Asia
Pacific
8.2.6.5.3.1. Market
Estimation, 2015 – 2020
8.2.6.5.3.2. Market
Forecast, 2021 – 2029
8.2.6.5.4. Middle
East and Africa
8.2.6.5.4.1. Market
Estimation, 2015 – 2020
8.2.6.5.4.2. Market
Forecast, 2021 – 2029
8.2.6.5.5. Latin
America
8.2.6.5.5.1. Market
Estimation, 2015 – 2020
8.2.6.5.5.2. Market
Forecast, 2021 – 2029
8.2.7. Mycobacterium
Tuberculosis (TB)
8.2.7.1. Definition
8.2.7.2. Market
Estimation and Penetration, 2015 – 2020
8.2.7.3. Market
Forecast, 2021 – 2029
8.2.7.4. Compound
Annual Growth Rate (CAGR)
8.2.7.5. Regional
Bifurcation
8.2.7.5.1. North
America
8.2.7.5.1.1. Market
Estimation, 2015 – 2020
8.2.7.5.1.2. Market
Forecast, 2021 – 2029
8.2.7.5.2. Europe
8.2.7.5.2.1. Market
Estimation, 2015 – 2020
8.2.7.5.2.2. Market
Forecast, 2021 – 2029
8.2.7.5.3. Asia
Pacific
8.2.7.5.3.1. Market
Estimation, 2015 – 2020
8.2.7.5.3.2. Market
Forecast, 2021 – 2029
8.2.7.5.4. Middle
East and Africa
8.2.7.5.4.1. Market
Estimation, 2015 – 2020
8.2.7.5.4.2. Market
Forecast, 2021 – 2029
8.2.7.5.5. Latin
America
8.2.7.5.5.1. Market
Estimation, 2015 – 2020
8.2.7.5.5.2. Market
Forecast, 2021 – 2029
8.2.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
8.2.8.1. Definition
8.2.8.2. Market
Estimation and Penetration, 2015 – 2020
8.2.8.3. Market
Forecast, 2021 – 2029
8.2.8.4. Compound
Annual Growth Rate (CAGR)
8.2.8.5. Regional
Bifurcation
8.2.8.5.1. North
America
8.2.8.5.1.1. Market
Estimation, 2015 – 2020
8.2.8.5.1.2. Market
Forecast, 2021 – 2029
8.2.8.5.2. Europe
8.2.8.5.2.1. Market
Estimation, 2015 – 2020
8.2.8.5.2.2. Market
Forecast, 2021 – 2029
8.2.8.5.3. Asia
Pacific
8.2.8.5.3.1. Market
Estimation, 2015 – 2020
8.2.8.5.3.2. Market
Forecast, 2021 – 2029
8.2.8.5.4. Middle
East and Africa
8.2.8.5.4.1. Market
Estimation, 2015 – 2020
8.2.8.5.4.2. Market
Forecast, 2021 – 2029
8.2.8.5.5. Latin
America
8.2.8.5.5.1. Market
Estimation, 2015 – 2020
8.2.8.5.5.2. Market
Forecast, 2021 – 2029
8.2.9. Others
8.2.9.1. Definition
8.2.9.2. Market
Estimation and Penetration, 2015 – 2020
8.2.9.3. Market
Forecast, 2021 – 2029
8.2.9.4. Compound
Annual Growth Rate (CAGR)
8.2.9.5. Regional
Bifurcation
8.2.9.5.1. North
America
8.2.9.5.1.1. Market
Estimation, 2015 – 2020
8.2.9.5.1.2. Market
Forecast, 2021 – 2029
8.2.9.5.2. Europe
8.2.9.5.2.1. Market
Estimation, 2015 – 2020
8.2.9.5.2.2. Market
Forecast, 2021 – 2029
8.2.9.5.3. Asia
Pacific
8.2.9.5.3.1. Market
Estimation, 2015 – 2020
8.2.9.5.3.2. Market
Forecast, 2021 – 2029
8.2.9.5.4. Middle
East and Africa
8.2.9.5.4.1. Market
Estimation, 2015 – 2020
8.2.9.5.4.2. Market
Forecast, 2021 – 2029
8.2.9.5.5. Latin
America
8.2.9.5.5.1. Market
Estimation, 2015 – 2020
8.2.9.5.5.2. Market
Forecast, 2021 – 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By
Resistant Bacteria Type
9. Global
Antibiotic Resistance Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
9.2.1. Complicated
Urinary Tract Infections (cUTI)
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2015 – 2020
9.2.1.3. Market
Forecast, 2021 – 2029
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2015 – 2020
9.2.1.5.1.2. Market
Forecast, 2021 – 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 – 2020
9.2.1.5.2.2. Market
Forecast, 2021 – 2029
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2015 – 2020
9.2.1.5.3.2. Market
Forecast, 2021 – 2029
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 – 2020
9.2.1.5.4.2. Market
Forecast, 2021 – 2029
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2015 – 2020
9.2.1.5.5.2. Market
Forecast, 2021 – 2029
9.2.2. Complicated
Intra-Abdominal Infections (cIAI)
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2020
9.2.2.3. Market
Forecast, 2021 – 2029
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2020
9.2.2.5.1.2. Market
Forecast, 2021 – 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2020
9.2.2.5.2.2. Market
Forecast, 2021 – 2029
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2020
9.2.2.5.3.2. Market
Forecast, 2021 – 2029
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2020
9.2.2.5.4.2. Market
Forecast, 2021 – 2029
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2020
9.2.2.5.5.2. Market
Forecast, 2021 – 2029
9.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2015 – 2020
9.2.3.3. Market
Forecast, 2021 – 2029
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 – 2020
9.2.3.5.1.2. Market
Forecast, 2021 – 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 – 2020
9.2.3.5.2.2. Market
Forecast, 2021 – 2029
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 – 2020
9.2.3.5.3.2. Market
Forecast, 2021 – 2029
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 – 2020
9.2.3.5.4.2. Market
Forecast, 2021 – 2029
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 – 2020
9.2.3.5.5.2. Market
Forecast, 2021 – 2029
9.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2015 – 2020
9.2.4.3. Market
Forecast, 2021 – 2029
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2015 – 2020
9.2.4.5.1.2. Market
Forecast, 2021 – 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 – 2020
9.2.4.5.2.2. Market
Forecast, 2021 – 2029
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2015 – 2020
9.2.4.5.3.2. Market
Forecast, 2021 – 2029
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 – 2020
9.2.4.5.4.2. Market
Forecast, 2021 – 2029
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2015 – 2020
9.2.4.5.5.2. Market
Forecast, 2021 – 2029
9.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2015 – 2020
9.2.5.3. Market
Forecast, 2021 – 2029
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2015 – 2020
9.2.5.5.1.2. Market
Forecast, 2021 – 2029
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 – 2020
9.2.5.5.2.2. Market
Forecast, 2021 – 2029
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2015 – 2020
9.2.5.5.3.2. Market
Forecast, 2021 – 2029
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 – 2020
9.2.5.5.4.2. Market
Forecast, 2021 – 2029
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2015 – 2020
9.2.5.5.5.2. Market
Forecast, 2021 – 2029
9.2.6. Sepsis
9.2.6.1. Definition
9.2.6.2. Market
Estimation and Penetration, 2015 – 2020
9.2.6.3. Market
Forecast, 2021 – 2029
9.2.6.4. Compound
Annual Growth Rate (CAGR)
9.2.6.5. Regional
Bifurcation
9.2.6.5.1. North
America
9.2.6.5.1.1. Market
Estimation, 2015 – 2020
9.2.6.5.1.2. Market
Forecast, 2021 – 2029
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 – 2020
9.2.6.5.2.2. Market
Forecast, 2021 – 2029
9.2.6.5.3. Asia
Pacific
9.2.6.5.3.1. Market
Estimation, 2015 – 2020
9.2.6.5.3.2. Market
Forecast, 2021 – 2029
9.2.6.5.4. Middle
East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 – 2020
9.2.6.5.4.2. Market
Forecast, 2021 – 2029
9.2.6.5.5. Latin
America
9.2.6.5.5.1. Market
Estimation, 2015 – 2020
9.2.6.5.5.2. Market
Forecast, 2021 – 2029
9.2.7. Clostridium
Difficile (C. difficile) Infections
9.2.7.1. Definition
9.2.7.2. Market
Estimation and Penetration, 2015 – 2020
9.2.7.3. Market
Forecast, 2021 – 2029
9.2.7.4. Compound
Annual Growth Rate (CAGR)
9.2.7.5. Regional
Bifurcation
9.2.7.5.1. North
America
9.2.7.5.1.1. Market
Estimation, 2015 – 2020
9.2.7.5.1.2. Market
Forecast, 2021 – 2029
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2015 – 2020
9.2.7.5.2.2. Market
Forecast, 2021 – 2029
9.2.7.5.3. Asia
Pacific
9.2.7.5.3.1. Market
Estimation, 2015 – 2020
9.2.7.5.3.2. Market
Forecast, 2021 – 2029
9.2.7.5.4. Middle
East and Africa
9.2.7.5.4.1. Market
Estimation, 2015 – 2020
9.2.7.5.4.2. Market
Forecast, 2021 – 2029
9.2.7.5.5. Latin
America
9.2.7.5.5.1. Market
Estimation, 2015 – 2020
9.2.7.5.5.2. Market
Forecast, 2021 – 2029
9.2.8. Others
9.2.8.1. Definition
9.2.8.2. Market
Estimation and Penetration, 2015 – 2020
9.2.8.3. Market
Forecast, 2021 – 2029
9.2.8.4. Compound
Annual Growth Rate (CAGR)
9.2.8.5. Regional
Bifurcation
9.2.8.5.1. North
America
9.2.8.5.1.1. Market
Estimation, 2015 – 2020
9.2.8.5.1.2. Market
Forecast, 2021 – 2029
9.2.8.5.2. Europe
9.2.8.5.2.1. Market
Estimation, 2015 – 2020
9.2.8.5.2.2. Market
Forecast, 2021 – 2029
9.2.8.5.3. Asia
Pacific
9.2.8.5.3.1. Market
Estimation, 2015 – 2020
9.2.8.5.3.2. Market
Forecast, 2021 – 2029
9.2.8.5.4. Middle
East and Africa
9.2.8.5.4.1. Market
Estimation, 2015 – 2020
9.2.8.5.4.2. Market
Forecast, 2021 – 2029
9.2.8.5.5. Latin
America
9.2.8.5.5.1. Market
Estimation, 2015 – 2020
9.2.8.5.5.2. Market
Forecast, 2021 – 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Disease Indication
10. Global
Antibiotic Resistance Market Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
10.2.1. Antimycobacterials
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 – 2020
10.2.1.3. Market
Forecast, 2021 – 2029
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 – 2020
10.2.1.5.1.2. Market
Forecast, 2021 – 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2020
10.2.1.5.2.2. Market
Forecast, 2021 – 2029
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2020
10.2.1.5.3.2. Market
Forecast, 2021 – 2029
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2020
10.2.1.5.4.2. Market
Forecast, 2021 – 2029
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 – 2020
10.2.1.5.5.2. Market
Forecast, 2021 – 2029
10.2.2. Fluoroquinolones
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 – 2020
10.2.2.3. Market
Forecast, 2021 – 2029
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 – 2020
10.2.2.5.1.2. Market
Forecast, 2021 – 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2020
10.2.2.5.2.2. Market
Forecast, 2021 – 2029
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2020
10.2.2.5.3.2. Market
Forecast, 2021 – 2029
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2020
10.2.2.5.4.2. Market
Forecast, 2021 – 2029
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 – 2020
10.2.2.5.5.2. Market
Forecast, 2021 – 2029
10.2.3. Oxazolidinones
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 – 2020
10.2.3.3. Market
Forecast, 2021 – 2029
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 – 2020
10.2.3.5.1.2. Market
Forecast, 2021 – 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2020
10.2.3.5.2.2. Market
Forecast, 2021 – 2029
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2020
10.2.3.5.3.2. Market
Forecast, 2021 – 2029
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2020
10.2.3.5.4.2. Market
Forecast, 2021 – 2029
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 – 2020
10.2.3.5.5.2. Market
Forecast, 2021 – 2029
10.2.4. Tetracyclines
10.2.4.1. Definition
10.2.4.2. Market
Estimation and Penetration, 2015 – 2020
10.2.4.3. Market
Forecast, 2021 – 2029
10.2.4.4. Compound
Annual Growth Rate (CAGR)
10.2.4.5. Regional
Bifurcation
10.2.4.5.1. North
America
10.2.4.5.1.1. Market
Estimation, 2015 – 2020
10.2.4.5.1.2. Market
Forecast, 2021 – 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 – 2020
10.2.4.5.2.2. Market
Forecast, 2021 – 2029
10.2.4.5.3. Asia
Pacific
10.2.4.5.3.1. Market
Estimation, 2015 – 2020
10.2.4.5.3.2. Market
Forecast, 2021 – 2029
10.2.4.5.4. Middle
East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 – 2020
10.2.4.5.4.2. Market
Forecast, 2021 – 2029
10.2.4.5.5. Latin
America
10.2.4.5.5.1. Market
Estimation, 2015 – 2020
10.2.4.5.5.2. Market
Forecast, 2021 – 2029
10.2.5. Penicillins
10.2.5.1. Definition
10.2.5.2. Market
Estimation and Penetration, 2015 – 2020
10.2.5.3. Market
Forecast, 2021 – 2029
10.2.5.4. Compound
Annual Growth Rate (CAGR)
10.2.5.5. Regional
Bifurcation
10.2.5.5.1. North
America
10.2.5.5.1.1. Market
Estimation, 2015 – 2020
10.2.5.5.1.2. Market
Forecast, 2021 – 2029
10.2.5.5.2. Europe
10.2.5.5.2.1. Market
Estimation, 2015 – 2020
10.2.5.5.2.2. Market
Forecast, 2021 – 2029
10.2.5.5.3. Asia
Pacific
10.2.5.5.3.1. Market
Estimation, 2015 – 2020
10.2.5.5.3.2. Market
Forecast, 2021 – 2029
10.2.5.5.4. Middle
East and Africa
10.2.5.5.4.1. Market
Estimation, 2015 – 2020
10.2.5.5.4.2. Market
Forecast, 2021 – 2029
10.2.5.5.5. Latin
America
10.2.5.5.5.1. Market
Estimation, 2015 – 2020
10.2.5.5.5.2. Market
Forecast, 2021 – 2029
10.2.6. Antifolates
10.2.6.1. Definition
10.2.6.2. Market
Estimation and Penetration, 2015 – 2020
10.2.6.3. Market
Forecast, 2021 – 2029
10.2.6.4. Compound
Annual Growth Rate (CAGR)
10.2.6.5. Regional
Bifurcation
10.2.6.5.1. North
America
10.2.6.5.1.1. Market
Estimation, 2015 – 2020
10.2.6.5.1.2. Market
Forecast, 2021 – 2029
10.2.6.5.2. Europe
10.2.6.5.2.1. Market
Estimation, 2015 – 2020
10.2.6.5.2.2. Market
Forecast, 2021 – 2029
10.2.6.5.3. Asia
Pacific
10.2.6.5.3.1. Market
Estimation, 2015 – 2020
10.2.6.5.3.2. Market
Forecast, 2021 – 2029
10.2.6.5.4. Middle
East and Africa
10.2.6.5.4.1. Market
Estimation, 2015 – 2020
10.2.6.5.4.2. Market
Forecast, 2021 – 2029
10.2.6.5.5. Latin
America
10.2.6.5.5.1. Market
Estimation, 2015 – 2020
10.2.6.5.5.2. Market
Forecast, 2021 – 2029
10.2.7. Combination
Treatment
10.2.7.1. Definition
10.2.7.2. Market
Estimation and Penetration, 2015 – 2020
10.2.7.3. Market
Forecast, 2021 – 2029
10.2.7.4. Compound
Annual Growth Rate (CAGR)
10.2.7.5. Regional
Bifurcation
10.2.7.5.1. North
America
10.2.7.5.1.1. Market
Estimation, 2015 – 2020
10.2.7.5.1.2. Market
Forecast, 2021 – 2029
10.2.7.5.2. Europe
10.2.7.5.2.1. Market
Estimation, 2015 – 2020
10.2.7.5.2.2. Market
Forecast, 2021 – 2029
10.2.7.5.3. Asia
Pacific
10.2.7.5.3.1. Market
Estimation, 2015 – 2020
10.2.7.5.3.2. Market
Forecast, 2021 – 2029
10.2.7.5.4. Middle
East and Africa
10.2.7.5.4.1. Market
Estimation, 2015 – 2020
10.2.7.5.4.2. Market
Forecast, 2021 – 2029
10.2.7.5.5. Latin
America
10.2.7.5.5.1. Market
Estimation, 2015 – 2020
10.2.7.5.5.2. Market
Forecast, 2021 – 2029
10.2.8. Others
10.2.8.1. Definition
10.2.8.2. Market
Estimation and Penetration, 2015 – 2020
10.2.8.3. Market
Forecast, 2021 – 2029
10.2.8.4. Compound
Annual Growth Rate (CAGR)
10.2.8.5. Regional
Bifurcation
10.2.8.5.1. North
America
10.2.8.5.1.1. Market
Estimation, 2015 – 2020
10.2.8.5.1.2. Market
Forecast, 2021 – 2029
10.2.8.5.2. Europe
10.2.8.5.2.1. Market
Estimation, 2015 – 2020
10.2.8.5.2.2. Market
Forecast, 2021 – 2029
10.2.8.5.3. Asia
Pacific
10.2.8.5.3.1. Market
Estimation, 2015 – 2020
10.2.8.5.3.2. Market
Forecast, 2021 – 2029
10.2.8.5.4. Middle
East and Africa
10.2.8.5.4.1. Market
Estimation, 2015 – 2020
10.2.8.5.4.2. Market
Forecast, 2021 – 2029
10.2.8.5.5. Latin
America
10.2.8.5.5.1. Market
Estimation, 2015 – 2020
10.2.8.5.5.2. Market
Forecast, 2021 – 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By Drug
Class
11. Global
Antibiotic Resistance Market Analysis and Forecasts, 2021 – 2029
11.1. Overview
11.2. Global
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
11.2.1. Oral
11.2.1.1. Definition
11.2.1.2. Market
Estimation and Penetration, 2015 – 2020
11.2.1.3. Market
Forecast, 2021 – 2029
11.2.1.4. Compound
Annual Growth Rate (CAGR)
11.2.1.5. Regional
Bifurcation
11.2.1.5.1. North
America
11.2.1.5.1.1. Market
Estimation, 2015 – 2020
11.2.1.5.1.2. Market
Forecast, 2021 – 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 – 2020
11.2.1.5.2.2. Market
Forecast, 2021 – 2029
11.2.1.5.3. Asia
Pacific
11.2.1.5.3.1. Market
Estimation, 2015 – 2020
11.2.1.5.3.2. Market
Forecast, 2021 – 2029
11.2.1.5.4. Middle
East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 – 2020
11.2.1.5.4.2. Market
Forecast, 2021 – 2029
11.2.1.5.5. Latin
America
11.2.1.5.5.1. Market
Estimation, 2015 – 2020
11.2.1.5.5.2. Market
Forecast, 2021 – 2029
11.2.2. Topical
11.2.2.1. Definition
11.2.2.2. Market
Estimation and Penetration, 2015 – 2020
11.2.2.3. Market
Forecast, 2021 – 2029
11.2.2.4. Compound
Annual Growth Rate (CAGR)
11.2.2.5. Regional
Bifurcation
11.2.2.5.1. North
America
11.2.2.5.1.1. Market
Estimation, 2015 – 2020
11.2.2.5.1.2. Market
Forecast, 2021 – 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 – 2020
11.2.2.5.2.2. Market
Forecast, 2021 – 2029
11.2.2.5.3. Asia
Pacific
11.2.2.5.3.1. Market
Estimation, 2015 – 2020
11.2.2.5.3.2. Market
Forecast, 2021 – 2029
11.2.2.5.4. Middle
East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 – 2020
11.2.2.5.4.2. Market
Forecast, 2021 – 2029
11.2.2.5.5. Latin
America
11.2.2.5.5.1. Market
Estimation, 2015 – 2020
11.2.2.5.5.2. Market
Forecast, 2021 – 2029
11.2.3. Intramuscular
11.2.3.1. Definition
11.2.3.2. Market
Estimation and Penetration, 2015 – 2020
11.2.3.3. Market
Forecast, 2021 – 2029
11.2.3.4. Compound
Annual Growth Rate (CAGR)
11.2.3.5. Regional
Bifurcation
11.2.3.5.1. North
America
11.2.3.5.1.1. Market
Estimation, 2015 – 2020
11.2.3.5.1.2. Market
Forecast, 2021 – 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 – 2020
11.2.3.5.2.2. Market
Forecast, 2021 – 2029
11.2.3.5.3. Asia
Pacific
11.2.3.5.3.1. Market
Estimation, 2015 – 2020
11.2.3.5.3.2. Market
Forecast, 2021 – 2029
11.2.3.5.4. Middle
East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 – 2020
11.2.3.5.4.2. Market
Forecast, 2021 – 2029
11.2.3.5.5. Latin
America
11.2.3.5.5.1. Market
Estimation, 2015 – 2020
11.2.3.5.5.2. Market
Forecast, 2021 – 2029
11.2.4. Intravenous
(IV)
11.2.4.1. Definition
11.2.4.2. Market
Estimation and Penetration, 2015 – 2020
11.2.4.3. Market
Forecast, 2021 – 2029
11.2.4.4. Compound
Annual Growth Rate (CAGR)
11.2.4.5. Regional
Bifurcation
11.2.4.5.1. North
America
11.2.4.5.1.1. Market
Estimation, 2015 – 2020
11.2.4.5.1.2. Market
Forecast, 2021 – 2029
11.2.4.5.2. Europe
11.2.4.5.2.1. Market
Estimation, 2015 – 2020
11.2.4.5.2.2. Market
Forecast, 2021 – 2029
11.2.4.5.3. Asia
Pacific
11.2.4.5.3.1. Market
Estimation, 2015 – 2020
11.2.4.5.3.2. Market
Forecast, 2021 – 2029
11.2.4.5.4. Middle
East and Africa
11.2.4.5.4.1. Market
Estimation, 2015 – 2020
11.2.4.5.4.2. Market
Forecast, 2021 – 2029
11.2.4.5.5. Latin
America
11.2.4.5.5.1. Market
Estimation, 2015 – 2020
11.2.4.5.5.2. Market
Forecast, 2021 – 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By Route
of Administration
12. Global
Antibiotic Resistance Market Analysis and Forecasts, 2021 – 2029
12.1. Overview
12.2. Global
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
12.2.1. Home
Care
12.2.1.1. Definition
12.2.1.2. Market
Estimation and Penetration, 2015 – 2020
12.2.1.3. Market
Forecast, 2021 – 2029
12.2.1.4. Compound
Annual Growth Rate (CAGR)
12.2.1.5. Regional
Bifurcation
12.2.1.5.1. North
America
12.2.1.5.1.1. Market
Estimation, 2015 – 2020
12.2.1.5.1.2. Market
Forecast, 2021 – 2029
12.2.1.5.2. Europe
12.2.1.5.2.1. Market
Estimation, 2015 – 2020
12.2.1.5.2.2. Market
Forecast, 2021 – 2029
12.2.1.5.3. Asia
Pacific
12.2.1.5.3.1. Market
Estimation, 2015 – 2020
12.2.1.5.3.2. Market
Forecast, 2021 – 2029
12.2.1.5.4. Middle
East and Africa
12.2.1.5.4.1. Market
Estimation, 2015 – 2020
12.2.1.5.4.2. Market
Forecast, 2021 – 2029
12.2.1.5.5. Latin
America
12.2.1.5.5.1. Market
Estimation, 2015 – 2020
12.2.1.5.5.2. Market
Forecast, 2021 – 2029
12.2.2. Healthcare
Facilities
12.2.2.1. Definition
12.2.2.2. Market
Estimation and Penetration, 2015 – 2020
12.2.2.3. Market
Forecast, 2021 – 2029
12.2.2.4. Compound
Annual Growth Rate (CAGR)
12.2.2.5. Regional
Bifurcation
12.2.2.5.1. North
America
12.2.2.5.1.1. Market
Estimation, 2015 – 2020
12.2.2.5.1.2. Market
Forecast, 2021 – 2029
12.2.2.5.2. Europe
12.2.2.5.2.1. Market
Estimation, 2015 – 2020
12.2.2.5.2.2. Market
Forecast, 2021 – 2029
12.2.2.5.3. Asia
Pacific
12.2.2.5.3.1. Market
Estimation, 2015 – 2020
12.2.2.5.3.2. Market
Forecast, 2021 – 2029
12.2.2.5.4. Middle
East and Africa
12.2.2.5.4.1. Market
Estimation, 2015 – 2020
12.2.2.5.4.2. Market
Forecast, 2021 – 2029
12.2.2.5.5. Latin
America
12.2.2.5.5.1. Market
Estimation, 2015 – 2020
12.2.2.5.5.2. Market
Forecast, 2021 – 2029
12.3. Key
Segment for Channeling Investments
12.3.1. By End
Use
13. North
America Antibiotic Resistance Market Analysis and Forecasts, 2020 - 2028
13.1. Overview
13.1.1. North
America Antibiotic Resistance Market Revenue (US$ Mn)
13.2. North
America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Resistant Bacteria Type
13.2.1. Pseudomonas
Aeruginosa
13.2.2. Clostridioides
difficile (C. difficile)
13.2.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
13.2.4. Streptococcus
pneumoniae (S. pneumoniae)
13.2.5. Acinetobacter
13.2.6. Vancomycin-resistant
Enterococci (VRE)
13.2.7. Mycobacterium
Tuberculosis (TB)
13.2.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
13.2.9. Others
13.3. North
America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.3.1. Complicated
Urinary Tract Infections (cUTI)
13.3.2. Complicated
Intra-Abdominal Infections (cIAI)
13.3.3. Community-Acquired
Bacterial Pneumonia (CABP)
13.3.4. Acute
Skin and Skin Structure Infections (ABSSSI)
13.3.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
13.3.6. Sepsis
13.3.7. Clostridium
Difficile (C. difficile) Infections
13.3.8. Others
13.4. North
America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug
Class
13.4.1. Antimycobacterials
13.4.2. Fluoroquinolones
13.4.3. Oxazolidinones
13.4.4. Tetracyclines
13.4.5. Penicillins
13.4.6. Antifolates
13.4.7. Combination
Treatment
13.4.8. Others
13.5. North
America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
13.5.1. Oral
13.5.2. Topical
13.5.3. Intramuscular
13.5.4. Intravenous
(IV)
13.6. North
America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
13.6.1. Home
Care
13.6.2. Healthcare
Facilities
13.7. North America
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1. U.S
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
13.7.1.1.1. Pseudomonas
Aeruginosa
13.7.1.1.2. Clostridioides
difficile (C. difficile)
13.7.1.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
13.7.1.1.4. Streptococcus
pneumoniae (S. pneumoniae)
13.7.1.1.5. Acinetobacter
13.7.1.1.6. Vancomycin-resistant
Enterococci (VRE)
13.7.1.1.7. Mycobacterium
Tuberculosis (TB)
13.7.1.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
13.7.1.1.9. Others
13.7.1.2. U.S
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.7.1.2.1. Complicated
Urinary Tract Infections (cUTI)
13.7.1.2.2. Complicated
Intra-Abdominal Infections (cIAI)
13.7.1.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
13.7.1.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
13.7.1.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
13.7.1.2.6. Sepsis
13.7.1.2.7. Clostridium
Difficile (C. difficile) Infections
13.7.1.2.8. Others
13.7.1.3. U.S
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.7.1.3.1. Antimycobacterials
13.7.1.3.2. Fluoroquinolones
13.7.1.3.3. Oxazolidinones
13.7.1.3.4. Tetracyclines
13.7.1.3.5. Penicillins
13.7.1.3.6. Antifolates
13.7.1.3.7. Combination
Treatment
13.7.1.3.8. Others
13.7.1.4. U.S
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.1.4.1. Oral
13.7.1.4.2. Topical
13.7.1.4.3. Intramuscular
13.7.1.4.4. Intravenous
(IV)
13.7.1.5. U.S
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
13.7.1.5.1. Home
Care
13.7.1.5.2. Healthcare
Facilities
13.7.2. Canada
13.7.2.1. Canada
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
13.7.2.1.1. Pseudomonas
Aeruginosa
13.7.2.1.2. Clostridioides
difficile (C. difficile)
13.7.2.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
13.7.2.1.4. Streptococcus
pneumoniae (S. pneumoniae)
13.7.2.1.5. Acinetobacter
13.7.2.1.6. Vancomycin-resistant
Enterococci (VRE)
13.7.2.1.7. Mycobacterium
Tuberculosis (TB)
13.7.2.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
13.7.2.1.9. Others
13.7.2.2. Canada
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.7.2.2.1. Complicated
Urinary Tract Infections (cUTI)
13.7.2.2.2. Complicated
Intra-Abdominal Infections (cIAI)
13.7.2.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
13.7.2.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
13.7.2.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
13.7.2.2.6. Sepsis
13.7.2.2.7. Clostridium
Difficile (C. difficile) Infections
13.7.2.2.8. Others
13.7.2.3. Canada
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.7.2.3.1. Antimycobacterials
13.7.2.3.2. Fluoroquinolones
13.7.2.3.3. Oxazolidinones
13.7.2.3.4. Tetracyclines
13.7.2.3.5. Penicillins
13.7.2.3.6. Antifolates
13.7.2.3.7. Combination
Treatment
13.7.2.3.8. Others
13.7.2.4. Canada
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.2.4.1. Oral
13.7.2.4.2. Topical
13.7.2.4.3. Intramuscular
13.7.2.4.4. Intravenous
(IV)
13.7.2.5. Canada
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
13.7.2.5.1. Home
Care
13.7.2.5.2. Healthcare
Facilities
13.7.3. Mexico
13.7.3.1. Mexico
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
13.7.3.1.1. Pseudomonas
Aeruginosa
13.7.3.1.2. Clostridioides
difficile (C. difficile)
13.7.3.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
13.7.3.1.4. Streptococcus
pneumoniae (S. pneumoniae)
13.7.3.1.5. Acinetobacter
13.7.3.1.6. Vancomycin-resistant
Enterococci (VRE)
13.7.3.1.7. Mycobacterium
Tuberculosis (TB)
13.7.3.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
13.7.3.1.9. Others
13.7.3.2. Mexico
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
13.7.3.2.1. Complicated
Urinary Tract Infections (cUTI)
13.7.3.2.2. Complicated
Intra-Abdominal Infections (cIAI)
13.7.3.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
13.7.3.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
13.7.3.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
13.7.3.2.6. Sepsis
13.7.3.2.7. Clostridium
Difficile (C. difficile) Infections
13.7.3.2.8. Others
13.7.3.3. Mexico
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
13.7.3.3.1. Antimycobacterials
13.7.3.3.2. Fluoroquinolones
13.7.3.3.3. Oxazolidinones
13.7.3.3.4. Tetracyclines
13.7.3.3.5. Penicillins
13.7.3.3.6. Antifolates
13.7.3.3.7. Combination
Treatment
13.7.3.3.8. Others
13.7.3.4. Mexico
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.3.4.1. Oral
13.7.3.4.2. Topical
13.7.3.4.3. Intramuscular
13.7.3.4.4. Intravenous
(IV)
13.7.3.5. Mexico
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
13.7.3.5.1. Home
Care
13.7.3.5.2. Healthcare
Facilities
13.7.4. Rest of
North America
13.7.4.1. Rest
of North America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts,
By Resistant Bacteria Type
13.7.4.1.1. Pseudomonas
Aeruginosa
13.7.4.1.2. Clostridioides
difficile (C. difficile)
13.7.4.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
13.7.4.1.4. Streptococcus
pneumoniae (S. pneumoniae)
13.7.4.1.5. Acinetobacter
13.7.4.1.6. Vancomycin-resistant
Enterococci (VRE)
13.7.4.1.7. Mycobacterium
Tuberculosis (TB)
13.7.4.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
13.7.4.1.9. Others
13.7.4.2. Rest
of North America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts,
By Disease Indication
13.7.4.2.1. Complicated
Urinary Tract Infections (cUTI)
13.7.4.2.2. Complicated
Intra-Abdominal Infections (cIAI)
13.7.4.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
13.7.4.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
13.7.4.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
13.7.4.2.6. Sepsis
13.7.4.2.7. Clostridium
Difficile (C. difficile) Infections
13.7.4.2.8. Others
13.7.4.3. Rest
of North America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts,
By Drug Class
13.7.4.3.1. Antimycobacterials
13.7.4.3.2. Fluoroquinolones
13.7.4.3.3. Oxazolidinones
13.7.4.3.4. Tetracyclines
13.7.4.3.5. Penicillins
13.7.4.3.6. Antifolates
13.7.4.3.7. Combination
Treatment
13.7.4.3.8. Others
13.7.4.4. Rest
of North America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
13.7.4.4.1. Oral
13.7.4.4.2. Topical
13.7.4.4.3. Intramuscular
13.7.4.4.4. Intravenous
(IV)
13.7.4.5. Rest
of North America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts,
By End Use
13.7.4.5.1. Home
Care
13.7.4.5.2. Healthcare
Facilities
13.8. Key
Segment for Channeling Investments
13.8.1. By Country
13.8.2. By
Resistant Bacteria Type
13.8.3. By
Disease Indication
13.8.4. By Drug
Class
13.8.5. By
Route of Administration
13.8.6. By End
Use
14. Europe
Antibiotic Resistance Market Analysis and Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Europe
Antibiotic Resistance Market Revenue (US$ Mn)
14.2. Europe
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
14.2.1. Pseudomonas
Aeruginosa
14.2.2. Clostridioides
difficile (C. difficile)
14.2.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
14.2.4. Streptococcus
pneumoniae (S. pneumoniae)
14.2.5. Acinetobacter
14.2.6. Vancomycin-resistant
Enterococci (VRE)
14.2.7. Mycobacterium
Tuberculosis (TB)
14.2.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
14.2.9. Others
14.3. Europe
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.3.1. Complicated
Urinary Tract Infections (cUTI)
14.3.2. Complicated
Intra-Abdominal Infections (cIAI)
14.3.3. Community-Acquired
Bacterial Pneumonia (CABP)
14.3.4. Acute
Skin and Skin Structure Infections (ABSSSI)
14.3.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
14.3.6. Sepsis
14.3.7. Clostridium
Difficile (C. difficile) Infections
14.3.8. Others
14.4. Europe
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.4.1. Antimycobacterials
14.4.2. Fluoroquinolones
14.4.3. Oxazolidinones
14.4.4. Tetracyclines
14.4.5. Penicillins
14.4.6. Antifolates
14.4.7. Combination
Treatment
14.4.8. Others
14.5. Europe Antibiotic
Resistance Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.5.1. Oral
14.5.2. Topical
14.5.3. Intramuscular
14.5.4. Intravenous
(IV)
14.6. Europe
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
14.6.1. Home
Care
14.6.2. Healthcare
Facilities
14.7. Europe
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Country
14.7.1. France
14.7.1.1. France
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
14.7.1.1.1. Pseudomonas
Aeruginosa
14.7.1.1.2. Clostridioides
difficile (C. difficile)
14.7.1.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
14.7.1.1.4. Streptococcus
pneumoniae (S. pneumoniae)
14.7.1.1.5. Acinetobacter
14.7.1.1.6. Vancomycin-resistant
Enterococci (VRE)
14.7.1.1.7. Mycobacterium
Tuberculosis (TB)
14.7.1.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
14.7.1.1.9. Others
14.7.1.2. France
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.7.1.2.1. Complicated
Urinary Tract Infections (cUTI)
14.7.1.2.2. Complicated
Intra-Abdominal Infections (cIAI)
14.7.1.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
14.7.1.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
14.7.1.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
14.7.1.2.6. Sepsis
14.7.1.2.7. Clostridium
Difficile (C. difficile) Infections
14.7.1.2.8. Others
14.7.1.3. France
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.7.1.3.1. Antimycobacterials
14.7.1.3.2. Fluoroquinolones
14.7.1.3.3. Oxazolidinones
14.7.1.3.4. Tetracyclines
14.7.1.3.5. Penicillins
14.7.1.3.6. Antifolates
14.7.1.3.7. Combination
Treatment
14.7.1.3.8. Others
14.7.1.4. France
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.1.4.1. Oral
14.7.1.4.2. Topical
14.7.1.4.3. Intramuscular
14.7.1.4.4. Intravenous
(IV)
14.7.1.5. France
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
14.7.1.5.1. Home
Care
14.7.1.5.2. Healthcare
Facilities
14.7.2. The UK
14.7.2.1. The
UK Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
14.7.2.1.1. Pseudomonas
Aeruginosa
14.7.2.1.2. Clostridioides
difficile (C. difficile)
14.7.2.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
14.7.2.1.4. Streptococcus
pneumoniae (S. pneumoniae)
14.7.2.1.5. Acinetobacter
14.7.2.1.6. Vancomycin-resistant
Enterococci (VRE)
14.7.2.1.7. Mycobacterium
Tuberculosis (TB)
14.7.2.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
14.7.2.1.9. Others
14.7.2.2. The
UK Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.7.2.2.1. Complicated
Urinary Tract Infections (cUTI)
14.7.2.2.2. Complicated
Intra-Abdominal Infections (cIAI)
14.7.2.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
14.7.2.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
14.7.2.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
14.7.2.2.6. Sepsis
14.7.2.2.7. Clostridium
Difficile (C. difficile) Infections
14.7.2.2.8. Others
14.7.2.3. The
UK Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.7.2.3.1. Antimycobacterials
14.7.2.3.2. Fluoroquinolones
14.7.2.3.3. Oxazolidinones
14.7.2.3.4. Tetracyclines
14.7.2.3.5. Penicillins
14.7.2.3.6. Antifolates
14.7.2.3.7. Combination
Treatment
14.7.2.3.8. Others
14.7.2.4. The
UK Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.2.4.1. Oral
14.7.2.4.2. Topical
14.7.2.4.3. Intramuscular
14.7.2.4.4. Intravenous
(IV)
14.7.2.5. The
UK Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
14.7.2.5.1. Home
Care
14.7.2.5.2. Healthcare
Facilities
14.7.3. Spain
14.7.3.1. Spain
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
14.7.3.1.1. Pseudomonas
Aeruginosa
14.7.3.1.2. Clostridioides
difficile (C. difficile)
14.7.3.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
14.7.3.1.4. Streptococcus
pneumoniae (S. pneumoniae)
14.7.3.1.5. Acinetobacter
14.7.3.1.6. Vancomycin-resistant
Enterococci (VRE)
14.7.3.1.7. Mycobacterium
Tuberculosis (TB)
14.7.3.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
14.7.3.1.9. Others
14.7.3.2. Spain
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.7.3.2.1. Complicated
Urinary Tract Infections (cUTI)
14.7.3.2.2. Complicated
Intra-Abdominal Infections (cIAI)
14.7.3.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
14.7.3.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
14.7.3.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
14.7.3.2.6. Sepsis
14.7.3.2.7. Clostridium
Difficile (C. difficile) Infections
14.7.3.2.8. Others
14.7.3.3. Spain
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.7.3.3.1. Antimycobacterials
14.7.3.3.2. Fluoroquinolones
14.7.3.3.3. Oxazolidinones
14.7.3.3.4. Tetracyclines
14.7.3.3.5. Penicillins
14.7.3.3.6. Antifolates
14.7.3.3.7. Combination
Treatment
14.7.3.3.8. Others
14.7.3.4. Spain
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.3.4.1. Oral
14.7.3.4.2. Topical
14.7.3.4.3. Intramuscular
14.7.3.4.4. Intravenous
(IV)
14.7.3.5. Spain
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
14.7.3.5.1. Home
Care
14.7.3.5.2. Healthcare
Facilities
14.7.4. Germany
14.7.4.1. Germany
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
14.7.4.1.1. Pseudomonas
Aeruginosa
14.7.4.1.2. Clostridioides
difficile (C. difficile)
14.7.4.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
14.7.4.1.4. Streptococcus
pneumoniae (S. pneumoniae)
14.7.4.1.5. Acinetobacter
14.7.4.1.6. Vancomycin-resistant
Enterococci (VRE)
14.7.4.1.7. Mycobacterium
Tuberculosis (TB)
14.7.4.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
14.7.4.1.9. Others
14.7.4.2. Germany
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.7.4.2.1. Complicated
Urinary Tract Infections (cUTI)
14.7.4.2.2. Complicated
Intra-Abdominal Infections (cIAI)
14.7.4.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
14.7.4.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
14.7.4.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
14.7.4.2.6. Sepsis
14.7.4.2.7. Clostridium
Difficile (C. difficile) Infections
14.7.4.2.8. Others
14.7.4.3. Germany
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.7.4.3.1. Antimycobacterials
14.7.4.3.2. Fluoroquinolones
14.7.4.3.3. Oxazolidinones
14.7.4.3.4. Tetracyclines
14.7.4.3.5. Penicillins
14.7.4.3.6. Antifolates
14.7.4.3.7. Combination
Treatment
14.7.4.3.8. Others
14.7.4.4. Germany
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.4.4.1. Oral
14.7.4.4.2. Topical
14.7.4.4.3. Intramuscular
14.7.4.4.4. Intravenous
(IV)
14.7.4.5. Germany
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
14.7.4.5.1. Home
Care
14.7.4.5.2. Healthcare
Facilities
14.7.5. Italy
14.7.5.1. Italy
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
14.7.5.1.1. Pseudomonas
Aeruginosa
14.7.5.1.2. Clostridioides
difficile (C. difficile)
14.7.5.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
14.7.5.1.4. Streptococcus
pneumoniae (S. pneumoniae)
14.7.5.1.5. Acinetobacter
14.7.5.1.6. Vancomycin-resistant
Enterococci (VRE)
14.7.5.1.7. Mycobacterium
Tuberculosis (TB)
14.7.5.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
14.7.5.1.9. Others
14.7.5.2. Italy
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.7.5.2.1. Complicated
Urinary Tract Infections (cUTI)
14.7.5.2.2. Complicated
Intra-Abdominal Infections (cIAI)
14.7.5.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
14.7.5.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
14.7.5.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
14.7.5.2.6. Sepsis
14.7.5.2.7. Clostridium
Difficile (C. difficile) Infections
14.7.5.2.8. Others
14.7.5.3. Italy
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
14.7.5.3.1. Antimycobacterials
14.7.5.3.2. Fluoroquinolones
14.7.5.3.3. Oxazolidinones
14.7.5.3.4. Tetracyclines
14.7.5.3.5. Penicillins
14.7.5.3.6. Antifolates
14.7.5.3.7. Combination
Treatment
14.7.5.3.8. Others
14.7.5.4. Italy
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.5.4.1. Oral
14.7.5.4.2. Topical
14.7.5.4.3. Intramuscular
14.7.5.4.4. Intravenous
(IV)
14.7.5.5. Italy
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
14.7.5.5.1. Home
Care
14.7.5.5.2. Healthcare
Facilities
14.7.6. Nordic
Countries
14.7.6.1. Nordic
Countries Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Resistant Bacteria Type
14.7.6.1.1. Pseudomonas
Aeruginosa
14.7.6.1.2. Clostridioides
difficile (C. difficile)
14.7.6.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
14.7.6.1.4. Streptococcus
pneumoniae (S. pneumoniae)
14.7.6.1.5. Acinetobacter
14.7.6.1.6. Vancomycin-resistant
Enterococci (VRE)
14.7.6.1.7. Mycobacterium
Tuberculosis (TB)
14.7.6.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
14.7.6.1.9. Others
14.7.6.2. Nordic
Countries Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
14.7.6.2.1. Complicated
Urinary Tract Infections (cUTI)
14.7.6.2.2. Complicated
Intra-Abdominal Infections (cIAI)
14.7.6.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
14.7.6.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
14.7.6.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
14.7.6.2.6. Sepsis
14.7.6.2.7. Clostridium
Difficile (C. difficile) Infections
14.7.6.2.8. Others
14.7.6.3. Nordic
Countries Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug
Class
14.7.6.3.1. Antimycobacterials
14.7.6.3.2. Fluoroquinolones
14.7.6.3.3. Oxazolidinones
14.7.6.3.4. Tetracyclines
14.7.6.3.5. Penicillins
14.7.6.3.6. Antifolates
14.7.6.3.7. Combination
Treatment
14.7.6.3.8. Others
14.7.6.4. Nordic
Countries Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.7.6.4.1. Oral
14.7.6.4.2. Topical
14.7.6.4.3. Intramuscular
14.7.6.4.4. Intravenous
(IV)
14.7.6.5. Nordic
Countries Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End
Use
14.7.6.5.1. Home
Care
14.7.6.5.2. Healthcare
Facilities
14.7.6.6. Nordic
Countries Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux
Union
14.7.7.1. Benelux
Union Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
14.7.7.1.1. Pseudomonas
Aeruginosa
14.7.7.1.2. Clostridioides
difficile (C. difficile)
14.7.7.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
14.7.7.1.4. Streptococcus
pneumoniae (S. pneumoniae)
14.7.7.1.5. Acinetobacter
14.7.7.1.6. Vancomycin-resistant
Enterococci (VRE)
14.7.7.1.7. Mycobacterium
Tuberculosis (TB)
14.7.7.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
14.7.7.1.9. Others
14.7.7.2. Benelux
Union Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
14.7.7.2.1. Complicated
Urinary Tract Infections (cUTI)
14.7.7.2.2. Complicated
Intra-Abdominal Infections (cIAI)
14.7.7.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
14.7.7.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
14.7.7.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
14.7.7.2.6. Sepsis
14.7.7.2.7. Clostridium
Difficile (C. difficile) Infections
14.7.7.2.8. Others
14.7.7.3. Benelux
Union Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug
Class
14.7.7.3.1. Antimycobacterials
14.7.7.3.2. Fluoroquinolones
14.7.7.3.3. Oxazolidinones
14.7.7.3.4. Tetracyclines
14.7.7.3.5. Penicillins
14.7.7.3.6. Antifolates
14.7.7.3.7. Combination
Treatment
14.7.7.3.8. Others
14.7.7.4. Benelux
Union Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.7.4.1. Oral
14.7.7.4.2. Topical
14.7.7.4.3. Intramuscular
14.7.7.4.4. Intravenous
(IV)
14.7.7.5. Benelux
Union Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
14.7.7.5.1. Home
Care
14.7.7.5.2. Healthcare
Facilities
14.7.7.6. Benelux
Union Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The
Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of
Europe
14.7.8.1. Rest
of Europe Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Resistant Bacteria Type
14.7.8.1.1. Pseudomonas
Aeruginosa
14.7.8.1.2. Clostridioides
difficile (C. difficile)
14.7.8.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
14.7.8.1.4. Streptococcus
pneumoniae (S. pneumoniae)
14.7.8.1.5. Acinetobacter
14.7.8.1.6. Vancomycin-resistant
Enterococci (VRE)
14.7.8.1.7. Mycobacterium
Tuberculosis (TB)
14.7.8.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
14.7.8.1.9. Others
14.7.8.2. Rest
of Europe Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
14.7.8.2.1. Complicated
Urinary Tract Infections (cUTI)
14.7.8.2.2. Complicated
Intra-Abdominal Infections (cIAI)
14.7.8.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
14.7.8.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
14.7.8.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
14.7.8.2.6. Sepsis
14.7.8.2.7. Clostridium
Difficile (C. difficile) Infections
14.7.8.2.8. Others
14.7.8.3. Rest
of Europe Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug
Class
14.7.8.3.1. Antimycobacterials
14.7.8.3.2. Fluoroquinolones
14.7.8.3.3. Oxazolidinones
14.7.8.3.4. Tetracyclines
14.7.8.3.5. Penicillins
14.7.8.3.6. Antifolates
14.7.8.3.7. Combination
Treatment
14.7.8.3.8. Others
14.7.8.4. Rest
of Europe Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.7.8.4.1. Oral
14.7.8.4.2. Topical
14.7.8.4.3. Intramuscular
14.7.8.4.4. Intravenous
(IV)
14.7.8.5. Rest
of Europe Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End
Use
14.7.8.5.1. Home
Care
14.7.8.5.2. Healthcare
Facilities
14.8. Key
Segment for Channeling Investments
14.8.1. By
Country
14.8.2. By
Resistant Bacteria Type
14.8.3. By
Disease Indication
14.8.4. By Drug
Class
14.8.5. By
Route of Administration
14.8.6. By End
Use
15. Asia
Pacific Antibiotic Resistance Market Analysis and Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Asia
Pacific Antibiotic Resistance Market Revenue (US$ Mn)
15.2. Asia
Pacific Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Resistant Bacteria Type
15.2.1. Pseudomonas
Aeruginosa
15.2.2. Clostridioides
difficile (C. difficile)
15.2.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
15.2.4. Streptococcus
pneumoniae (S. pneumoniae)
15.2.5. Acinetobacter
15.2.6. Vancomycin-resistant
Enterococci (VRE)
15.2.7. Mycobacterium
Tuberculosis (TB)
15.2.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
15.2.9. Others
15.3. Asia
Pacific Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.3.1. Complicated
Urinary Tract Infections (cUTI)
15.3.2. Complicated
Intra-Abdominal Infections (cIAI)
15.3.3. Community-Acquired
Bacterial Pneumonia (CABP)
15.3.4. Acute
Skin and Skin Structure Infections (ABSSSI)
15.3.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
15.3.6. Sepsis
15.3.7. Clostridium
Difficile (C. difficile) Infections
15.3.8. Others
15.4. Asia
Pacific Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug
Class
15.4.1. Antimycobacterials
15.4.2. Fluoroquinolones
15.4.3. Oxazolidinones
15.4.4. Tetracyclines
15.4.5. Penicillins
15.4.6. Antifolates
15.4.7. Combination
Treatment
15.4.8. Others
15.5. Asia
Pacific Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.5.1. Oral
15.5.2. Topical
15.5.3. Intramuscular
15.5.4. Intravenous
(IV)
15.6. Asia
Pacific Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
15.6.1. Home
Care
15.6.2. Healthcare
Facilities
15.7. Asia
Pacific Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1. China
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
15.7.1.1.1. Pseudomonas
Aeruginosa
15.7.1.1.2. Clostridioides
difficile (C. difficile)
15.7.1.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
15.7.1.1.4. Streptococcus
pneumoniae (S. pneumoniae)
15.7.1.1.5. Acinetobacter
15.7.1.1.6. Vancomycin-resistant
Enterococci (VRE)
15.7.1.1.7. Mycobacterium
Tuberculosis (TB)
15.7.1.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
15.7.1.1.9. Others
15.7.1.2. China
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.7.1.2.1. Complicated
Urinary Tract Infections (cUTI)
15.7.1.2.2. Complicated
Intra-Abdominal Infections (cIAI)
15.7.1.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
15.7.1.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
15.7.1.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
15.7.1.2.6. Sepsis
15.7.1.2.7. Clostridium
Difficile (C. difficile) Infections
15.7.1.2.8. Others
15.7.1.3. China
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.7.1.3.1. Antimycobacterials
15.7.1.3.2. Fluoroquinolones
15.7.1.3.3. Oxazolidinones
15.7.1.3.4. Tetracyclines
15.7.1.3.5. Penicillins
15.7.1.3.6. Antifolates
15.7.1.3.7. Combination
Treatment
15.7.1.3.8. Others
15.7.1.4. China
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.1.4.1. Oral
15.7.1.4.2. Topical
15.7.1.4.3. Intramuscular
15.7.1.4.4. Intravenous
(IV)
15.7.1.5. China
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.1.5.1. Home
Care
15.7.1.5.2. Healthcare
Facilities
15.7.2. Japan
15.7.2.1. Japan
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
15.7.2.1.1. Pseudomonas
Aeruginosa
15.7.2.1.2. Clostridioides
difficile (C. difficile)
15.7.2.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
15.7.2.1.4. Streptococcus
pneumoniae (S. pneumoniae)
15.7.2.1.5. Acinetobacter
15.7.2.1.6. Vancomycin-resistant
Enterococci (VRE)
15.7.2.1.7. Mycobacterium
Tuberculosis (TB)
15.7.2.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
15.7.2.1.9. Others
15.7.2.2. Japan
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.7.2.2.1. Complicated
Urinary Tract Infections (cUTI)
15.7.2.2.2. Complicated
Intra-Abdominal Infections (cIAI)
15.7.2.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
15.7.2.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
15.7.2.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
15.7.2.2.6. Sepsis
15.7.2.2.7. Clostridium
Difficile (C. difficile) Infections
15.7.2.2.8. Others
15.7.2.3. Japan
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.7.2.3.1. Antimycobacterials
15.7.2.3.2. Fluoroquinolones
15.7.2.3.3. Oxazolidinones
15.7.2.3.4. Tetracyclines
15.7.2.3.5. Penicillins
15.7.2.3.6. Antifolates
15.7.2.3.7. Combination
Treatment
15.7.2.3.8. Others
15.7.2.4. Japan
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.2.4.1. Oral
15.7.2.4.2. Topical
15.7.2.4.3. Intramuscular
15.7.2.4.4. Intravenous
(IV)
15.7.2.5. Japan
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.2.5.1. Home
Care
15.7.2.5.2. Healthcare
Facilities
15.7.3. India
15.7.3.1. India
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
15.7.3.1.1. Pseudomonas
Aeruginosa
15.7.3.1.2. Clostridioides
difficile (C. difficile)
15.7.3.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
15.7.3.1.4. Streptococcus
pneumoniae (S. pneumoniae)
15.7.3.1.5. Acinetobacter
15.7.3.1.6. Vancomycin-resistant
Enterococci (VRE)
15.7.3.1.7. Mycobacterium
Tuberculosis (TB)
15.7.3.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
15.7.3.1.9. Others
15.7.3.2. India
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.7.3.2.1. Complicated
Urinary Tract Infections (cUTI)
15.7.3.2.2. Complicated
Intra-Abdominal Infections (cIAI)
15.7.3.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
15.7.3.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
15.7.3.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
15.7.3.2.6. Sepsis
15.7.3.2.7. Clostridium
Difficile (C. difficile) Infections
15.7.3.2.8. Others
15.7.3.3. India
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.7.3.3.1. Antimycobacterials
15.7.3.3.2. Fluoroquinolones
15.7.3.3.3. Oxazolidinones
15.7.3.3.4. Tetracyclines
15.7.3.3.5. Penicillins
15.7.3.3.6. Antifolates
15.7.3.3.7. Combination
Treatment
15.7.3.3.8. Others
15.7.3.4. India
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.3.4.1. Oral
15.7.3.4.2. Topical
15.7.3.4.3. Intramuscular
15.7.3.4.4. Intravenous
(IV)
15.7.3.5. India
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.3.5.1. Home
Care
15.7.3.5.2. Healthcare
Facilities
15.7.4. New
Zealand
15.7.4.1. New
Zealand Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Resistant Bacteria Type
15.7.4.1.1. Pseudomonas
Aeruginosa
15.7.4.1.2. Clostridioides
difficile (C. difficile)
15.7.4.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
15.7.4.1.4. Streptococcus
pneumoniae (S. pneumoniae)
15.7.4.1.5. Acinetobacter
15.7.4.1.6. Vancomycin-resistant
Enterococci (VRE)
15.7.4.1.7. Mycobacterium
Tuberculosis (TB)
15.7.4.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
15.7.4.1.9. Others
15.7.4.2. New
Zealand Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.7.4.2.1. Complicated
Urinary Tract Infections (cUTI)
15.7.4.2.2. Complicated
Intra-Abdominal Infections (cIAI)
15.7.4.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
15.7.4.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
15.7.4.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
15.7.4.2.6. Sepsis
15.7.4.2.7. Clostridium
Difficile (C. difficile) Infections
15.7.4.2.8. Others
15.7.4.3. New
Zealand Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug
Class
15.7.4.3.1. Antimycobacterials
15.7.4.3.2. Fluoroquinolones
15.7.4.3.3. Oxazolidinones
15.7.4.3.4. Tetracyclines
15.7.4.3.5. Penicillins
15.7.4.3.6. Antifolates
15.7.4.3.7. Combination
Treatment
15.7.4.3.8. Others
15.7.4.4. New
Zealand Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.7.4.4.1. Oral
15.7.4.4.2. Topical
15.7.4.4.3. Intramuscular
15.7.4.4.4. Intravenous
(IV)
15.7.4.5. New
Zealand Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.4.5.1. Home
Care
15.7.4.5.2. Healthcare
Facilities
15.7.5. Australia
15.7.5.1. Australia
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
15.7.5.1.1. Pseudomonas
Aeruginosa
15.7.5.1.2. Clostridioides
difficile (C. difficile)
15.7.5.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
15.7.5.1.4. Streptococcus
pneumoniae (S. pneumoniae)
15.7.5.1.5. Acinetobacter
15.7.5.1.6. Vancomycin-resistant
Enterococci (VRE)
15.7.5.1.7. Mycobacterium
Tuberculosis (TB)
15.7.5.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
15.7.5.1.9. Others
15.7.5.2. Australia
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.7.5.2.1. Complicated
Urinary Tract Infections (cUTI)
15.7.5.2.2. Complicated
Intra-Abdominal Infections (cIAI)
15.7.5.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
15.7.5.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
15.7.5.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
15.7.5.2.6. Sepsis
15.7.5.2.7. Clostridium
Difficile (C. difficile) Infections
15.7.5.2.8. Others
15.7.5.3. Australia
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.7.5.3.1. Antimycobacterials
15.7.5.3.2. Fluoroquinolones
15.7.5.3.3. Oxazolidinones
15.7.5.3.4. Tetracyclines
15.7.5.3.5. Penicillins
15.7.5.3.6. Antifolates
15.7.5.3.7. Combination
Treatment
15.7.5.3.8. Others
15.7.5.4. Australia
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.5.4.1. Oral
15.7.5.4.2. Topical
15.7.5.4.3. Intramuscular
15.7.5.4.4. Intravenous
(IV)
15.7.5.5. Australia
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.5.5.1. Home
Care
15.7.5.5.2. Healthcare
Facilities
15.7.6. South
Korea
15.7.6.1. South
Korea Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
15.7.6.1.1. Pseudomonas
Aeruginosa
15.7.6.1.2. Clostridioides
difficile (C. difficile)
15.7.6.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
15.7.6.1.4. Streptococcus
pneumoniae (S. pneumoniae)
15.7.6.1.5. Acinetobacter
15.7.6.1.6. Vancomycin-resistant
Enterococci (VRE)
15.7.6.1.7. Mycobacterium
Tuberculosis (TB)
15.7.6.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
15.7.6.1.9. Others
15.7.6.2. South
Korea Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.7.6.2.1. Complicated
Urinary Tract Infections (cUTI)
15.7.6.2.2. Complicated
Intra-Abdominal Infections (cIAI)
15.7.6.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
15.7.6.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
15.7.6.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
15.7.6.2.6. Sepsis
15.7.6.2.7. Clostridium
Difficile (C. difficile) Infections
15.7.6.2.8. Others
15.7.6.3. South
Korea Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug
Class
15.7.6.3.1. Antimycobacterials
15.7.6.3.2. Fluoroquinolones
15.7.6.3.3. Oxazolidinones
15.7.6.3.4. Tetracyclines
15.7.6.3.5. Penicillins
15.7.6.3.6. Antifolates
15.7.6.3.7. Combination
Treatment
15.7.6.3.8. Others
15.7.6.4. South
Korea Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.6.4.1. Oral
15.7.6.4.2. Topical
15.7.6.4.3. Intramuscular
15.7.6.4.4. Intravenous
(IV)
15.7.6.5. South
Korea Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.6.5.1. Home
Care
15.7.6.5.2. Healthcare
Facilities
15.7.7. Southeast
Asia
15.7.7.1. Southeast
Asia Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
15.7.7.1.1. Pseudomonas
Aeruginosa
15.7.7.1.2. Clostridioides
difficile (C. difficile)
15.7.7.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
15.7.7.1.4. Streptococcus
pneumoniae (S. pneumoniae)
15.7.7.1.5. Acinetobacter
15.7.7.1.6. Vancomycin-resistant
Enterococci (VRE)
15.7.7.1.7. Mycobacterium
Tuberculosis (TB)
15.7.7.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
15.7.7.1.9. Others
15.7.7.2. Southeast
Asia Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
15.7.7.2.1. Complicated
Urinary Tract Infections (cUTI)
15.7.7.2.2. Complicated
Intra-Abdominal Infections (cIAI)
15.7.7.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
15.7.7.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
15.7.7.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
15.7.7.2.6. Sepsis
15.7.7.2.7. Clostridium
Difficile (C. difficile) Infections
15.7.7.2.8. Others
15.7.7.3. Southeast
Asia Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
15.7.7.3.1. Antimycobacterials
15.7.7.3.2. Fluoroquinolones
15.7.7.3.3. Oxazolidinones
15.7.7.3.4. Tetracyclines
15.7.7.3.5. Penicillins
15.7.7.3.6. Antifolates
15.7.7.3.7. Combination
Treatment
15.7.7.3.8. Others
15.7.7.4. Southeast
Asia Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.7.4.1. Oral
15.7.7.4.2. Topical
15.7.7.4.3. Intramuscular
15.7.7.4.4. Intravenous
(IV)
15.7.7.5. Southeast
Asia Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
15.7.7.5.1. Home
Care
15.7.7.5.2. Healthcare
Facilities
15.7.7.6. Southeast
Asia Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest
of Southeast Asia
15.7.8. Rest of
Asia Pacific
15.7.8.1. Rest
of Asia Pacific Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Resistant Bacteria Type
15.7.8.1.1. Pseudomonas
Aeruginosa
15.7.8.1.2. Clostridioides
difficile (C. difficile)
15.7.8.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
15.7.8.1.4. Streptococcus
pneumoniae (S. pneumoniae)
15.7.8.1.5. Acinetobacter
15.7.8.1.6. Vancomycin-resistant
Enterococci (VRE)
15.7.8.1.7. Mycobacterium
Tuberculosis (TB)
15.7.8.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
15.7.8.1.9. Others
15.7.8.2. Rest
of Asia Pacific Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
15.7.8.2.1. Complicated
Urinary Tract Infections (cUTI)
15.7.8.2.2. Complicated
Intra-Abdominal Infections (cIAI)
15.7.8.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
15.7.8.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
15.7.8.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
15.7.8.2.6. Sepsis
15.7.8.2.7. Clostridium
Difficile (C. difficile) Infections
15.7.8.2.8. Others
15.7.8.3. Rest
of Asia Pacific Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Drug Class
15.7.8.3.1. Antimycobacterials
15.7.8.3.2. Fluoroquinolones
15.7.8.3.3. Oxazolidinones
15.7.8.3.4. Tetracyclines
15.7.8.3.5. Penicillins
15.7.8.3.6. Antifolates
15.7.8.3.7. Combination
Treatment
15.7.8.3.8. Others
15.7.8.4. Rest
of Asia Pacific Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.8.4.1. Oral
15.7.8.4.2. Topical
15.7.8.4.3. Intramuscular
15.7.8.4.4. Intravenous
(IV)
15.7.8.5. Rest
of Asia Pacific Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
End Use
15.7.8.5.1. Home
Care
15.7.8.5.2. Healthcare
Facilities
15.8. Key
Segment for Channeling Investments
15.8.1. By
Country
15.8.2. By
Resistant Bacteria Type
15.8.3. By
Disease Indication
15.8.4. By Drug
Class
15.8.5. By
Route of Administration
15.8.6. By End
Use
16. Middle
East and Africa Antibiotic Resistance Market Analysis and Forecasts, 2020 -
2028
16.1. Overview
16.1.1. Middle
East and Africa Antibiotic Resistance Market Revenue (US$ Mn)
16.2. Middle
East and Africa Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Resistant Bacteria Type
16.2.1. Pseudomonas
Aeruginosa
16.2.2. Clostridioides
difficile (C. difficile)
16.2.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
16.2.4. Streptococcus
pneumoniae (S. pneumoniae)
16.2.5. Acinetobacter
16.2.6. Vancomycin-resistant
Enterococci (VRE)
16.2.7. Mycobacterium
Tuberculosis (TB)
16.2.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
16.2.9. Others
16.3. Middle
East and Africa Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Disease Indication
16.3.1. Complicated
Urinary Tract Infections (cUTI)
16.3.2. Complicated
Intra-Abdominal Infections (cIAI)
16.3.3. Community-Acquired
Bacterial Pneumonia (CABP)
16.3.4. Acute
Skin and Skin Structure Infections (ABSSSI)
16.3.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
16.3.6. Sepsis
16.3.7. Clostridium
Difficile (C. difficile) Infections
16.3.8. Others
16.4. Middle
East and Africa Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Drug Class
16.4.1. Antimycobacterials
16.4.2. Fluoroquinolones
16.4.3. Oxazolidinones
16.4.4. Tetracyclines
16.4.5. Penicillins
16.4.6. Antifolates
16.4.7. Combination
Treatment
16.4.8. Others
16.5. Middle
East and Africa Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.5.1. Oral
16.5.2. Topical
16.5.3. Intramuscular
16.5.4. Intravenous
(IV)
16.6. Middle
East and Africa Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
End Use
16.6.1. Home
Care
16.6.2. Healthcare
Facilities
16.7. Middle
East and Africa Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Country
16.7.1. Saudi
Arabia
16.7.1.1. Saudi
Arabia Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Resistant Bacteria Type
16.7.1.1.1. Pseudomonas
Aeruginosa
16.7.1.1.2. Clostridioides
difficile (C. difficile)
16.7.1.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
16.7.1.1.4. Streptococcus
pneumoniae (S. pneumoniae)
16.7.1.1.5. Acinetobacter
16.7.1.1.6. Vancomycin-resistant
Enterococci (VRE)
16.7.1.1.7. Mycobacterium
Tuberculosis (TB)
16.7.1.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
16.7.1.1.9. Others
16.7.1.2. Saudi
Arabia Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.7.1.2.1. Complicated
Urinary Tract Infections (cUTI)
16.7.1.2.2. Complicated
Intra-Abdominal Infections (cIAI)
16.7.1.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
16.7.1.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
16.7.1.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
16.7.1.2.6. Sepsis
16.7.1.2.7. Clostridium
Difficile (C. difficile) Infections
16.7.1.2.8. Others
16.7.1.3. Saudi
Arabia Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug
Class
16.7.1.3.1. Antimycobacterials
16.7.1.3.2. Fluoroquinolones
16.7.1.3.3. Oxazolidinones
16.7.1.3.4. Tetracyclines
16.7.1.3.5. Penicillins
16.7.1.3.6. Antifolates
16.7.1.3.7. Combination
Treatment
16.7.1.3.8. Others
16.7.1.4. Saudi
Arabia Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.1.4.1. Oral
16.7.1.4.2. Topical
16.7.1.4.3. Intramuscular
16.7.1.4.4. Intravenous
(IV)
16.7.1.5. Saudi
Arabia Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
16.7.1.5.1. Home
Care
16.7.1.5.2. Healthcare
Facilities
16.7.2. UAE
16.7.2.1. UAE
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
16.7.2.1.1. Pseudomonas
Aeruginosa
16.7.2.1.2. Clostridioides
difficile (C. difficile)
16.7.2.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
16.7.2.1.4. Streptococcus
pneumoniae (S. pneumoniae)
16.7.2.1.5. Acinetobacter
16.7.2.1.6. Vancomycin-resistant
Enterococci (VRE)
16.7.2.1.7. Mycobacterium
Tuberculosis (TB)
16.7.2.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
16.7.2.1.9. Others
16.7.2.2. UAE
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.7.2.2.1. Complicated
Urinary Tract Infections (cUTI)
16.7.2.2.2. Complicated
Intra-Abdominal Infections (cIAI)
16.7.2.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
16.7.2.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
16.7.2.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
16.7.2.2.6. Sepsis
16.7.2.2.7. Clostridium
Difficile (C. difficile) Infections
16.7.2.2.8. Others
16.7.2.3. UAE
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.7.2.3.1. Antimycobacterials
16.7.2.3.2. Fluoroquinolones
16.7.2.3.3. Oxazolidinones
16.7.2.3.4. Tetracyclines
16.7.2.3.5. Penicillins
16.7.2.3.6. Antifolates
16.7.2.3.7. Combination
Treatment
16.7.2.3.8. Others
16.7.2.4. UAE
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.2.4.1. Oral
16.7.2.4.2. Topical
16.7.2.4.3. Intramuscular
16.7.2.4.4. Intravenous
(IV)
16.7.2.5. UAE Antibiotic
Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
16.7.2.5.1. Home
Care
16.7.2.5.2. Healthcare
Facilities
16.7.3. Egypt
16.7.3.1. Egypt
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
16.7.3.1.1. Pseudomonas
Aeruginosa
16.7.3.1.2. Clostridioides
difficile (C. difficile)
16.7.3.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
16.7.3.1.4. Streptococcus
pneumoniae (S. pneumoniae)
16.7.3.1.5. Acinetobacter
16.7.3.1.6. Vancomycin-resistant
Enterococci (VRE)
16.7.3.1.7. Mycobacterium
Tuberculosis (TB)
16.7.3.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
16.7.3.1.9. Others
16.7.3.2. Egypt
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.7.3.2.1. Complicated
Urinary Tract Infections (cUTI)
16.7.3.2.2. Complicated
Intra-Abdominal Infections (cIAI)
16.7.3.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
16.7.3.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
16.7.3.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
16.7.3.2.6. Sepsis
16.7.3.2.7. Clostridium
Difficile (C. difficile) Infections
16.7.3.2.8. Others
16.7.3.3. Egypt
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.7.3.3.1. Antimycobacterials
16.7.3.3.2. Fluoroquinolones
16.7.3.3.3. Oxazolidinones
16.7.3.3.4. Tetracyclines
16.7.3.3.5. Penicillins
16.7.3.3.6. Antifolates
16.7.3.3.7. Combination
Treatment
16.7.3.3.8. Others
16.7.3.4. Egypt
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.3.4.1. Oral
16.7.3.4.2. Topical
16.7.3.4.3. Intramuscular
16.7.3.4.4. Intravenous
(IV)
16.7.3.5. Egypt
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
16.7.3.5.1. Home
Care
16.7.3.5.2. Healthcare
Facilities
16.7.4. Kuwait
16.7.4.1. Kuwait
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
16.7.4.1.1. Pseudomonas
Aeruginosa
16.7.4.1.2. Clostridioides
difficile (C. difficile)
16.7.4.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
16.7.4.1.4. Streptococcus
pneumoniae (S. pneumoniae)
16.7.4.1.5. Acinetobacter
16.7.4.1.6. Vancomycin-resistant
Enterococci (VRE)
16.7.4.1.7. Mycobacterium
Tuberculosis (TB)
16.7.4.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
16.7.4.1.9. Others
16.7.4.2. Kuwait
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.7.4.2.1. Complicated
Urinary Tract Infections (cUTI)
16.7.4.2.2. Complicated
Intra-Abdominal Infections (cIAI)
16.7.4.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
16.7.4.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
16.7.4.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
16.7.4.2.6. Sepsis
16.7.4.2.7. Clostridium
Difficile (C. difficile) Infections
16.7.4.2.8. Others
16.7.4.3. Kuwait
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
16.7.4.3.1. Antimycobacterials
16.7.4.3.2. Fluoroquinolones
16.7.4.3.3. Oxazolidinones
16.7.4.3.4. Tetracyclines
16.7.4.3.5. Penicillins
16.7.4.3.6. Antifolates
16.7.4.3.7. Combination
Treatment
16.7.4.3.8. Others
16.7.4.4. Kuwait
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.4.4.1. Oral
16.7.4.4.2. Topical
16.7.4.4.3. Intramuscular
16.7.4.4.4. Intravenous
(IV)
16.7.4.5. Kuwait
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
16.7.4.5.1. Home
Care
16.7.4.5.2. Healthcare
Facilities
16.7.5. South
Africa
16.7.5.1. South
Africa Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Resistant Bacteria Type
16.7.5.1.1. Pseudomonas
Aeruginosa
16.7.5.1.2. Clostridioides
difficile (C. difficile)
16.7.5.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
16.7.5.1.4. Streptococcus
pneumoniae (S. pneumoniae)
16.7.5.1.5. Acinetobacter
16.7.5.1.6. Vancomycin-resistant
Enterococci (VRE)
16.7.5.1.7. Mycobacterium
Tuberculosis (TB)
16.7.5.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
16.7.5.1.9. Others
16.7.5.2. South
Africa Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
16.7.5.2.1. Complicated
Urinary Tract Infections (cUTI)
16.7.5.2.2. Complicated
Intra-Abdominal Infections (cIAI)
16.7.5.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
16.7.5.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
16.7.5.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
16.7.5.2.6. Sepsis
16.7.5.2.7. Clostridium
Difficile (C. difficile) Infections
16.7.5.2.8. Others
16.7.5.3. South
Africa Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug
Class
16.7.5.3.1. Antimycobacterials
16.7.5.3.2. Fluoroquinolones
16.7.5.3.3. Oxazolidinones
16.7.5.3.4. Tetracyclines
16.7.5.3.5. Penicillins
16.7.5.3.6. Antifolates
16.7.5.3.7. Combination
Treatment
16.7.5.3.8. Others
16.7.5.4. South
Africa Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.5.4.1. Oral
16.7.5.4.2. Topical
16.7.5.4.3. Intramuscular
16.7.5.4.4. Intravenous
(IV)
16.7.5.5. South
Africa Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
16.7.5.5.1. Home
Care
16.7.5.5.2. Healthcare
Facilities
16.7.6. Rest of
Middle East & Africa
16.7.6.1. Rest
of Middle East & Africa Antibiotic Resistance Market Revenue (US$ Mn) and
Forecasts, By Resistant Bacteria Type
16.7.6.1.1. Pseudomonas
Aeruginosa
16.7.6.1.2. Clostridioides
difficile (C. difficile)
16.7.6.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
16.7.6.1.4. Streptococcus
pneumoniae (S. pneumoniae)
16.7.6.1.5. Acinetobacter
16.7.6.1.6. Vancomycin-resistant
Enterococci (VRE)
16.7.6.1.7. Mycobacterium
Tuberculosis (TB)
16.7.6.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
16.7.6.1.9. Others
16.7.6.2. Rest
of Middle East & Africa Antibiotic Resistance Market Revenue (US$ Mn) and
Forecasts, By Disease Indication
16.7.6.2.1. Complicated
Urinary Tract Infections (cUTI)
16.7.6.2.2. Complicated
Intra-Abdominal Infections (cIAI)
16.7.6.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
16.7.6.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
16.7.6.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
16.7.6.2.6. Sepsis
16.7.6.2.7. Clostridium
Difficile (C. difficile) Infections
16.7.6.2.8. Others
16.7.6.3. Rest
of Middle East & Africa Antibiotic Resistance Market Revenue (US$ Mn) and
Forecasts, By Drug Class
16.7.6.3.1. Antimycobacterials
16.7.6.3.2. Fluoroquinolones
16.7.6.3.3. Oxazolidinones
16.7.6.3.4. Tetracyclines
16.7.6.3.5. Penicillins
16.7.6.3.6. Antifolates
16.7.6.3.7. Combination
Treatment
16.7.6.3.8. Others
16.7.6.4. Rest
of Middle East & Africa Antibiotic Resistance Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.7.6.4.1. Oral
16.7.6.4.2. Topical
16.7.6.4.3. Intramuscular
16.7.6.4.4. Intravenous
(IV)
16.7.6.5. Rest
of Middle East & Africa Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts,
By End Use
16.7.6.5.1. Home
Care
16.7.6.5.2. Healthcare
Facilities
16.8. Key
Segment for Channeling Investments
16.8.1. By
Country
16.8.2. By
Resistant Bacteria Type
16.8.3. By
Disease Indication
16.8.4. By Drug
Class
16.8.5. By
Route of Administration
16.8.6. By End
Use
17. Latin
America Antibiotic Resistance Market Analysis and Forecasts, 2020 - 2028
17.1. Overview
17.1.1. Latin
America Antibiotic Resistance Market Revenue (US$ Mn)
17.2. Latin
America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By
Resistant Bacteria Type
17.2.1. Pseudomonas
Aeruginosa
17.2.2. Clostridioides
difficile (C. difficile)
17.2.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
17.2.4. Streptococcus
pneumoniae (S. pneumoniae)
17.2.5. Acinetobacter
17.2.6. Vancomycin-resistant
Enterococci (VRE)
17.2.7. Mycobacterium
Tuberculosis (TB)
17.2.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
17.2.9. Others
17.3. Latin
America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
17.3.1. Complicated
Urinary Tract Infections (cUTI)
17.3.2. Complicated
Intra-Abdominal Infections (cIAI)
17.3.3. Community-Acquired
Bacterial Pneumonia (CABP)
17.3.4. Acute
Skin and Skin Structure Infections (ABSSSI)
17.3.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
17.3.6. Sepsis
17.3.7. Clostridium
Difficile (C. difficile) Infections
17.3.8. Others
17.4. Latin
America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug
Class
17.4.1. Antimycobacterials
17.4.2. Fluoroquinolones
17.4.3. Oxazolidinones
17.4.4. Tetracyclines
17.4.5. Penicillins
17.4.6. Antifolates
17.4.7. Combination
Treatment
17.4.8. Others
17.5. Latin
America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
17.5.1. Oral
17.5.2. Topical
17.5.3. Intramuscular
17.5.4. Intravenous
(IV)
17.6. Latin
America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
17.6.1. Home
Care
17.6.2. Healthcare
Facilities
17.7. Latin
America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1. Brazil
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
17.7.1.1.1. Pseudomonas
Aeruginosa
17.7.1.1.2. Clostridioides
difficile (C. difficile)
17.7.1.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
17.7.1.1.4. Streptococcus
pneumoniae (S. pneumoniae)
17.7.1.1.5. Acinetobacter
17.7.1.1.6. Vancomycin-resistant
Enterococci (VRE)
17.7.1.1.7. Mycobacterium
Tuberculosis (TB)
17.7.1.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
17.7.1.1.9. Others
17.7.1.2. Brazil
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
17.7.1.2.1. Complicated
Urinary Tract Infections (cUTI)
17.7.1.2.2. Complicated
Intra-Abdominal Infections (cIAI)
17.7.1.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
17.7.1.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
17.7.1.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
17.7.1.2.6. Sepsis
17.7.1.2.7. Clostridium
Difficile (C. difficile) Infections
17.7.1.2.8. Others
17.7.1.3. Brazil
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
17.7.1.3.1. Antimycobacterials
17.7.1.3.2. Fluoroquinolones
17.7.1.3.3. Oxazolidinones
17.7.1.3.4. Tetracyclines
17.7.1.3.5. Penicillins
17.7.1.3.6. Antifolates
17.7.1.3.7. Combination
Treatment
17.7.1.3.8. Others
17.7.1.4. Brazil
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.7.1.4.1. Oral
17.7.1.4.2. Topical
17.7.1.4.3. Intramuscular
17.7.1.4.4. Intravenous
(IV)
17.7.1.5. Brazil
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
17.7.1.5.1. Home
Care
17.7.1.5.2. Healthcare
Facilities
17.7.2. Argentina
17.7.2.1. Argentina
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Resistant
Bacteria Type
17.7.2.1.1. Pseudomonas
Aeruginosa
17.7.2.1.2. Clostridioides
difficile (C. difficile)
17.7.2.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
17.7.2.1.4. Streptococcus
pneumoniae (S. pneumoniae)
17.7.2.1.5. Acinetobacter
17.7.2.1.6. Vancomycin-resistant
Enterococci (VRE)
17.7.2.1.7. Mycobacterium
Tuberculosis (TB)
17.7.2.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
17.7.2.1.9. Others
17.7.2.2. Argentina
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Disease
Indication
17.7.2.2.1. Complicated
Urinary Tract Infections (cUTI)
17.7.2.2.2. Complicated
Intra-Abdominal Infections (cIAI)
17.7.2.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
17.7.2.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
17.7.2.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
17.7.2.2.6. Sepsis
17.7.2.2.7. Clostridium
Difficile (C. difficile) Infections
17.7.2.2.8. Others
17.7.2.3. Argentina
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Drug Class
17.7.2.3.1. Antimycobacterials
17.7.2.3.2. Fluoroquinolones
17.7.2.3.3. Oxazolidinones
17.7.2.3.4. Tetracyclines
17.7.2.3.5. Penicillins
17.7.2.3.6. Antifolates
17.7.2.3.7. Combination
Treatment
17.7.2.3.8. Others
17.7.2.4. Argentina
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.7.2.4.1. Oral
17.7.2.4.2. Topical
17.7.2.4.3. Intramuscular
17.7.2.4.4. Intravenous
(IV)
17.7.2.5. Argentina
Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts, By End Use
17.7.2.5.1. Home
Care
17.7.2.5.2. Healthcare
Facilities
17.7.3. Rest of
Latin America
17.7.3.1. Rest
of Latin America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts,
By Resistant Bacteria Type
17.7.3.1.1. Pseudomonas
Aeruginosa
17.7.3.1.2. Clostridioides
difficile (C. difficile)
17.7.3.1.3. Carbapenem-resistant
Enterobacteriaceae (CRE)
17.7.3.1.4. Streptococcus
pneumoniae (S. pneumoniae)
17.7.3.1.5. Acinetobacter
17.7.3.1.6. Vancomycin-resistant
Enterococci (VRE)
17.7.3.1.7. Mycobacterium
Tuberculosis (TB)
17.7.3.1.8. Neisseria
gonorrhoeae (N. gonorrhoeae)
17.7.3.1.9. Others
17.7.3.2. Rest
of Latin America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts,
By Disease Indication
17.7.3.2.1. Complicated
Urinary Tract Infections (cUTI)
17.7.3.2.2. Complicated
Intra-Abdominal Infections (cIAI)
17.7.3.2.3. Community-Acquired
Bacterial Pneumonia (CABP)
17.7.3.2.4. Acute
Skin and Skin Structure Infections (ABSSSI)
17.7.3.2.5. Multidrug-Resistant
(MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB
and XDR-TB)
17.7.3.2.6. Sepsis
17.7.3.2.7. Clostridium
Difficile (C. difficile) Infections
17.7.3.2.8. Others
17.7.3.3. Rest
of Latin America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts,
By Drug Class
17.7.3.3.1. Antimycobacterials
17.7.3.3.2. Fluoroquinolones
17.7.3.3.3. Oxazolidinones
17.7.3.3.4. Tetracyclines
17.7.3.3.5. Penicillins
17.7.3.3.6. Antifolates
17.7.3.3.7. Combination
Treatment
17.7.3.3.8. Others
17.7.3.4. Rest
of Latin America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
17.7.3.4.1. Oral
17.7.3.4.2. Topical
17.7.3.4.3. Intramuscular
17.7.3.4.4. Intravenous
(IV)
17.7.3.5. Rest
of Latin America Antibiotic Resistance Market Revenue (US$ Mn) and Forecasts,
By End Use
17.7.3.5.1. Home
Care
17.7.3.5.2. Healthcare
Facilities
17.8. Key
Segment for Channeling Investments
17.8.1. By
Country
17.8.2. By
Resistant Bacteria Type
17.8.3. By
Disease Indication
17.8.4. By Drug
Class
17.8.5. By
Route of Administration
17.8.6. By End
Use
18. Competitive
Benchmarking
18.1. Market
Share Analysis, 2019
18.2. Global
Presence and Growth Strategies
18.2.1. Mergers
and Acquisitions
18.2.2. Product
Launches
18.2.3. Investments
Trends
18.2.4. R&D
Initiatives
19. Player
Profiles
19.1. Allergan
Pharma Co.
19.1.1. Company
Details
19.1.2. Company
Overview
19.1.3. Product
Offerings
19.1.4. Key
Developments
19.1.5. Financial
Analysis
19.1.6. SWOT
Analysis
19.1.7. Business
Strategies
19.2. GlaxoSmithKline
plc.
19.2.1. Company
Details
19.2.2. Company
Overview
19.2.3. Product
Offerings
19.2.4. Key
Developments
19.2.5. Financial
Analysis
19.2.6. SWOT
Analysis
19.2.7. Business
Strategies
19.3. Johnson
& Johnson Services, Inc.
19.3.1. Company
Details
19.3.2. Company
Overview
19.3.3. Product
Offerings
19.3.4. Key
Developments
19.3.5. Financial
Analysis
19.3.6. SWOT
Analysis
19.3.7. Business
Strategies
19.4. MELINTA THERAPEUTICS - THE
ANTIBIOTICS COMPANY
19.4.1. Company
Details
19.4.2. Company
Overview
19.4.3. Product
Offerings
19.4.4. Key
Developments
19.4.5. Financial
Analysis
19.4.6. SWOT
Analysis
19.4.7. Business Strategies
19.5. Merck
& Co., Inc.
19.5.1. Company
Details
19.5.2. Company
Overview
19.5.3. Product
Offerings
19.5.4. Key
Developments
19.5.5. Financial
Analysis
19.5.6. SWOT
Analysis
19.5.7. Business
Strategies
19.6. Mylan
N.V.
19.6.1. Company
Details
19.6.2. Company
Overview
19.6.3. Product
Offerings
19.6.4. Key
Developments
19.6.5. Financial
Analysis
19.6.6. SWOT
Analysis
19.6.7. Business
Strategies
19.7. Nabriva Therapeutics plc
19.7.1. Company
Details
19.7.2. Company
Overview
19.7.3. Product
Offerings
19.7.4. Key
Developments
19.7.5. Financial
Analysis
19.7.6. SWOT
Analysis
19.7.7. Business Strategies
19.8. Otsuka
Novel Products GmbH
19.8.1. Company
Details
19.8.2. Company
Overview
19.8.3. Product
Offerings
19.8.4. Key
Developments
19.8.5. Financial
Analysis
19.8.6. SWOT
Analysis
19.8.7. Business
Strategies
19.9. Pfizer
Inc.
19.9.1. Company
Details
19.9.2. Company
Overview
19.9.3. Product
Offerings
19.9.4. Key
Developments
19.9.5. Financial
Analysis
19.9.6. SWOT
Analysis
19.9.7. Business
Strategies
19.10. Sandoz
AG
19.10.1. Company
Details
19.10.2. Company
Overview
19.10.3. Product
Offerings
19.10.4. Key
Developments
19.10.5. Financial
Analysis
19.10.6. SWOT
Analysis
19.10.7. Business
Strategies
19.11. Other
Market participants
20. Key
Findings
Note: This ToC is
tentative and can be changed according to the research study conducted during
the course of report completion.
**Exclusive for
Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.